Romero-Gómez M, Turnes J, Ampuero J, Oyagüez I, Cuenca B, González-García J, Muñoz-Molina B, Aguilar R, Leal S, Planas R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Casado MA, Solà R
Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: The Optim Study
PLoS One.2015;10(3):e0122613.doi:10.1371/journal.pone.0122613
Gros B, Soto J, Casado MA
Incorporation of future costs in health economic analysis publications: Current situation and recommendations for the future
Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):465-9
Mar J, Masjuan J, Oliva-Moreno J, Gonzalez-Rojas N, Becerra V, Casado MA, Torres C, Yebenes M, Quintana M, Alvarez-Sabín J
Outcomes measured by mortality rates, quality of life and degree of autonomy in the first year in Stroke Units in Spain
Health Qual Life Outcomes. 2015;13:36. doi: 10.1186/s12955-015-0230-8
Roncero C, Domínguez-Hernández R, Díaz T, Fernández JM, Forcada R, Martínez JM, Seijo P, Terán A, Oyagüez I
Manejo de pacientes dependientes de opiáceos: Comparación del coste asociado al uso de buprenorfina/naloxona o metadona, y sus interacciones con tratamientos concomitantes para comorbilidades infecciosas o psiquiátricas
Adicciones. 2015;27(3):179-89
Villarrubia R, Oyagüez I, Alvarez-Roman MT, Mingot-Castellano ME, Parra R, Casado MA
Cost analysis of prophylaxis with activated prothrombin complex concéntrate versus on-demand therapy with activated factor VII in severe hemophilia A patients with inhibitors, in Spain
Haemophilia. 2015;21(3):320-9
Grau S, Lozano V, Valladares A, Cavanillas R, Xie Y, Nocea G
Impact of dynamic microbiological environment on the clinical efficacy of ertapenem and piperacillin/tazobactam in the treatment of complicated community-acquired intra-abdominal infection in Spain: A cost-consequence analysis
Appl Health Econ Health Policy. 2015;13(4):369-79
Arevalo JM, Lozano V, Oyagüez I, Casado MA